Study on Pharmanex tegreen 97® Finds Benefits in Blood Sugar Control and Weight Loss

Company News

Printer Friendly Version View printer-friendly version << Back
June 2, 2005 at 12:00 AM EDT

Study on Pharmanex tegreen 97® Finds Benefits in Blood Sugar Control and Weight Loss

Pharmanex Scientists Invited to Present Landmark Study at Recent American Heart Association Meeting

PROVO, UT – June 2, 2005 – Pharmanex, a Nu Skin Enterprises company (NYSE: NUS), announced today a study that found Tegreen 97® to provide blood sugar control, body fat burning properties and weight-loss benefits in an experimental setting of Metabolic Syndrome X subjects – a precursor to type-2 diabetes. The findings of the new study were recently presented at the American Heart Association's Sixth Annual Conference in Washington, D.C.

“We are honored by the American Heart Association's invitation to present our newest findings on Tegreen 97,” said Joe Chang, Ph.D., president of Pharmanex. “The results of this study are very meaningful in building a greater body of knowledge related to two significant health issues today: weight gain and lack of blood sugar control. We have shown with this and other studies that Tegreen 97 can have a significant beneficial effect in managing these two health conditions.”

Tegreen 97® is a proprietary, decaffeinated green tea extract standardized to 97 percent polyphenols — two-thirds of which are catechins, the element responsible for the observed effect. Each capsule of Tegreen 97® contains the same amount of catechins as seven cups of the traditionally brewed green tea drink.

Nu Skin Enterprises
June 2, 2005
Page 2 of 3
About the Study

The purpose of this study was to examine the effects of Tegreen 97® in enhancing insulin sensitivity and improving glucose-lipid metabolism. In addition, the research examined the effects of the proprietary green tea supplement in lowering body weight and weight of abdominal fat and inhibiting angiogenesis, which is the formation and differentiation of blood vessels, a key pathological process in the development of abnormal cells. Angiogenesis is hypothesized to play an important role in development of obesity. Following are the results of the study:

• Tegreen 97® enhanced insulin sensitivity* • Improved glucose-lipid metabolism* • Increased fat burning and decreased body fat percentage* • Lowered body weight associated with inhibited angiogenesis.*

“Our findings proved that in addition to its significance in protecting cells from abnormal mutation, inhibition of angiogenesis by Tegreen 97 is associated with reduction of body weight,” said Josh Zhu, senior director of clinical R&D for Pharmanex and chief researcher of the study. “Tegreen 97 not only supports the general belief in the anti-aging benefits of tea catechins but may also provide benefits to people with Metabolic Syndrome X, overweight and those with subsequent cardiovascular and brain health concerns.”

Tegreen 97® is also included in LifePak®, the company's comprehensive multivitamin/mineral and antioxidant supplement.


Pharmanex, a Nu Skin Enterprises company, applies pharmaceutical processes and scientific measurement to create nutritional supplements for more than 40 markets worldwide. Pharmanex® products are sold direct to the consumer through the Internet and a network of independent distributors. For more information, go to

Nu Skin Enterprises
June 2, 2005
Page 3 of 3

The Company

Nu Skin Enterprises, Inc. is a global direct selling company operating in 40 markets throughout Asia, the Americas and Europe. The company markets premium quality personal care products under the Nu Skin® brand, science-based nutritional supplements under the Pharmanex® brand, and technology based products and services under the Big Planet® brand. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol “NUS.”

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.